8 European Projects Found
Searched on 125080 European Projects
FINISHED
Development of Biomaterial-based Delivery Systems for Parkinson’s disease - an Integrated Pan-European Approach (BrainMatTrain)
Start date: Jan 1, 2016, End date: Dec 31, 2019,
BrainMatTrain focuses on a comprehensive understanding of Parkinson’s disease (PD), from basics to translation, fully supported by 8 full partners partner organisation (4 research institutions, 2 hospitals, 2 SMEs) and one partner organisation (SME specialist in device design). This ETN will educate and train 15 Earlty Stage Researchers (ESRs) in functioanlised biomaterials, materials science, fun ...
Read Project
8
Partners Participants
FINISHED
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM)
Start date: May 1, 2015, End date: Apr 30, 2019,
Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in particular, diabetic kidney disease (DKD), which is already the most common cause of chronic kidney disease. DKD is associated with greatly increased mortality and frequently progresses to end stage renal failure. Pharmacotherapy, dialysis and transplantation repr ...
Read Project
12
Partners Participants
FINISHED
Adverse Immune Signatures and their Prevention in Corneal Transplantation (VISICORT)
Start date: Apr 1, 2014, End date: Mar 31, 2019,
"Immune system response is the most complex barrier to long-term success of tissue transplants/implants from allogeneic and bio-artificial sources. While newly developed tissue transplant procedures are not yet performed frequently enough for robust analysis of adverse immune responses in humans, corneal transplantation (CT) is a well-established allogeneic tissue transplant with >100,000 full- an ...
Read Project
12
Partners Participants
FINISHED
Development of closed, scalable and AUTOmated robotic systems for therapeutic STEM cell manufacturing: aseptic systems from “Donor-to-Patient” (AUTOSTEM)
Start date: Jan 1, 2016, End date: Dec 31, 2018,
AUTOSTEM will develop closed, scaleable and automated systems for therapeutic cell manufacture. The project vision is a donor-to-patient system where all aspects of processing, from tissue harvest to patient delivery are fully closed and aseptic. The process will involve new methods of biological cell selection from marrow, fat or other tissues, bioreactors to achieve scale and media formulations ...
Read Project
10
Partners Participants
FINISHED
MEsenchymal stem cells to Reduce Liver INflammation (MERLIN)
Start date: Feb 1, 2014, End date: Jan 31, 2018,
"Prevalence of liver disease is c6% (29 million people) in the EU with mortality rates from chronic liver diseases estimated at 14.3 per 100.000 in the EU-25 in 2004. Most liver diseases have a significant inflammatory component that underpins liver damage and fibrogenesis, yet current therapies have limited effectiveness. Safe novel anti-inflammatory therapies would satisfy a large unmet need for ...
Read Project
9
Partners Participants
FINISHED
Decision-making within cells and differentiation entity therapies (DECIDE)
Start date: Mar 1, 2013, End date: Feb 28, 2017,
"Our ITN has both scientific and therapeutic targets. Research in Work Package 1 (WP1) aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). Research in WP2 will use the information gained from WP1 to develop ways of alleviating the differentiation block in AML and so deliver new agents for use in differentiat ...
Read Project
8
Partners Participants
FINISHED
Repair of Diabetic Damage by Stromal Cell Administration (REDDSTAR)
Start date: Nov 1, 2012, End date: Oct 31, 2016,
50 million diabetic EU citizens are using approved anti-diabetic agents to control their glycaemia. However, suboptimal glycemic control leads to 6 progressive diabetic complications, namely: nephropathy, retinopathy, cardiomyopathy, neuropathy and foot ulceration. In 2010, 11% of EU adult deaths (634,000) were caused by diabetic complications. These distinct disorders have few effective medicines ...
Read Project
10
Partners Participants
FINISHED
Utilisation of the mesenchymal stem cell receptome for rational development of uniform, serum-free culture conditions and tools for cell characterization (PurStem)
Start date: Nov 1, 2008, End date: Apr 30, 2012,
Stem cells offer a promising avenue to therapy for a wide range of complaints. However, for this potential to be realized, a consistent and plentiful supply of well-characterised stem cells is essential. There has been relatively little progress in the development of new culture technologies for the large-scale manufacture of mesenchymal stem cells (MSCs). There is a strong possibility that this ...
Read Project
